Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study

M.C. Dubinsky; P.M. Irving; X.Y. Li; S. Howaldt; J. Pokrotnieks; K.A. Krueger; J. Laskowski; T. Lissoos; J. Milata; N. Morris; V. Arora; C. Milch; B.E. Sands

doi:10.1016/S0016-5085(22)64060-5

Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study

M.C. Dubinsky, P.M. Irving, X.Y. Li, S. Howaldt, J. Pokrotnieks, K.A. Krueger, J. Laskowski, T. Lissoos, J. Milata, N. Morris, V. Arora, C. Milch, B.E. Sands

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	867e
Pages (from-to)	S1393-S1394
Number of pages	2
Journal	Gastroenterology
Volume	162
Issue number	7
DOIs	https://doi.org/10.1016/S0016-5085(22)64060-5
Publication status	Published - May 2022
Externally published	Yes
Event	Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW): Bidirectional Learning – a foundation for excellence & innovation - Sidney, Australia Duration: 9 Sept 2022 → 11 Sept 2022 https://agw.gesa.org.au/ https://www.emedevents.com/medical-hybrid-events-2022/gastroenterological-society-of-australia-gesa-australian-gastroenterology-week-agw-2022

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

10.1016/S0016-5085(22)64060-5

Cite this

Dubinsky, M. C., Irving, P. M., Li, X. Y., Howaldt, S., Pokrotnieks, J., Krueger, K. A., Laskowski, J., Lissoos, T., Milata, J., Morris, N., Arora, V., Milch, C., & Sands, B. E. (2022). Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study. Gastroenterology, 162(7), S1393-S1394. Article 867e. https://doi.org/10.1016/S0016-5085(22)64060-5

@article{38e02d55e8f243768fcf9362b6d39c0e,

title = "Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study",

author = "M.C. Dubinsky and P.M. Irving and X.Y. Li and S. Howaldt and J. Pokrotnieks and K.A. Krueger and J. Laskowski and T. Lissoos and J. Milata and N. Morris and V. Arora and C. Milch and B.E. Sands",

year = "2022",

month = may,

doi = "10.1016/S0016-5085(22)64060-5",

language = "English",

volume = "162",

pages = "S1393--S1394",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "7",

note = "Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) : Bidirectional Learning – a foundation for excellence & innovation, GESA AGW 2022 ; Conference date: 09-09-2022 Through 11-09-2022",

url = "https://agw.gesa.org.au/, https://www.emedevents.com/medical-hybrid-events-2022/gastroenterological-society-of-australia-gesa-australian-gastroenterology-week-agw-2022",

}

Dubinsky, MC, Irving, PM, Li, XY, Howaldt, S, Pokrotnieks, J, Krueger, KA, Laskowski, J, Lissoos, T, Milata, J, Morris, N, Arora, V, Milch, C & Sands, BE 2022, 'Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study', Gastroenterology, vol. 162, no. 7, 867e, pp. S1393-S1394. https://doi.org/10.1016/S0016-5085(22)64060-5

TY - JOUR

T1 - Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

T2 - Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW)

AU - Dubinsky, M.C.

AU - Irving, P.M.

AU - Li, X.Y.

AU - Howaldt, S.

AU - Pokrotnieks, J.

AU - Krueger, K.A.

AU - Laskowski, J.

AU - Lissoos, T.

AU - Milata, J.

AU - Morris, N.

AU - Arora, V.

AU - Milch, C.

AU - Sands, B.E.

PY - 2022/5

Y1 - 2022/5

UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/WOS:000826446205409

U2 - 10.1016/S0016-5085(22)64060-5

DO - 10.1016/S0016-5085(22)64060-5

M3 - Meeting Abstract

SN - 0016-5085

VL - 162

SP - S1393-S1394

JO - Gastroenterology

JF - Gastroenterology

IS - 7

M1 - 867e

Y2 - 9 September 2022 through 11 September 2022

ER -

Efficacy and Safety of Mirikizumab As Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 Lucent-2 Study

Field of Science*

Publication Type*

Access to Document

Other files and links

Efficacy and safety of mirikizumab as maintenance therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-2 study

Cite this